Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$201.36 +1.4%	$190.39	$163.81 ▼ $218.66	$350.91B	0.5	5.08 million shs	3.56 million shs
AMGN Amgen	$289.33 +1.5%	$293.12	$253.30 ▼ $339.17	$153.42B	0.49	2.12 million shs	1.78 million shs
BMY Bristol Myers Squibb	$47.82 +2.7%	$47.23	$42.96 ▼ $63.33	$94.75B	0.36	13.23 million shs	10.11 million shs
JNJ Johnson & Johnson	$174.29 +0.9%	$160.42	$140.68 ▼ $174.76	$416.11B	0.41	9.39 million shs	5.87 million shs
MRK Merck & Co., Inc.	$82.67 +3.0%	$80.97	$73.31 ▼ $120.30	$200.57B	0.38	11.99 million shs	11.04 million shs
MRNA Moderna	$26.89 +4.8%	$29.18	$23.15 ▼ $91.99	$9.98B	1.83	8.45 million shs	8.65 million shs
UNH UnitedHealth Group	$271.92 +4.0%	$289.37	$234.60 ▼ $630.73	$236.90B	0.43	18.29 million shs	19.33 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+0.05%	+0.02%	+3.24%	+11.99%	+4.39%
AMGN Amgen	-0.04%	-5.03%	-3.48%	+8.65%	-10.94%
BMY Bristol Myers Squibb	+1.26%	+1.46%	-0.90%	+5.52%	-1.27%
JNJ Johnson & Johnson	-0.68%	+1.23%	+10.15%	+18.04%	+8.08%
MRK Merck & Co., Inc.	+0.25%	-0.61%	-3.67%	+9.30%	-29.27%
MRNA Moderna	+0.75%	-6.59%	-23.72%	+6.83%	-68.43%
UNH UnitedHealth Group	+3.63%	+4.12%	-13.90%	-15.16%	-53.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.7517 of 5 stars	2.5	4.0	3.3	3.9	4.0	2.5	1.3
AMGN Amgen	4.6283 of 5 stars	2.2	3.0	3.3	3.9	3.4	2.5	1.9
BMY Bristol Myers Squibb	4.7033 of 5 stars	2.1	4.0	4.2	4.0	3.5	2.5	1.3
JNJ Johnson & Johnson	4.7069 of 5 stars	2.3	3.0	4.2	3.9	3.7	1.7	1.9
MRK Merck & Co., Inc.	4.9949 of 5 stars	3.2	5.0	5.0	4.2	3.1	1.7	3.8
MRNA Moderna	4.3271 of 5 stars	4.0	1.0	0.0	4.6	2.3	2.5	0.6
UNH UnitedHealth Group	4.9941 of 5 stars	4.3	3.0	4.2	4.0	3.4	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.93	Moderate Buy	$214.95	6.75% Upside
AMGN Amgen	2.33	Hold	$303.76	4.99% Upside
BMY Bristol Myers Squibb	2.24	Hold	$56.38	17.89% Upside
JNJ Johnson & Johnson	2.65	Moderate Buy	$174.50	0.12% Upside
MRK Merck & Co., Inc.	2.35	Hold	$107.44	29.96% Upside
MRNA Moderna	2.04	Hold	$43.59	62.10% Upside
UNH UnitedHealth Group	2.50	Moderate Buy	$366.52	34.79% Upside

Current Analyst Ratings Breakdown

Latest MRK, JNJ, UNH, AMGN, MRNA, BMY, and ABBV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$231.00
8/7/2025	ABBV AbbVie	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/7/2025	ABBV AbbVie	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$214.00
8/6/2025	AMGN Amgen	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$305.00 ➝ $310.00
8/6/2025	AMGN Amgen	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$330.00 ➝ $333.00
8/6/2025	AMGN Amgen	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$326.00 ➝ $317.00
8/6/2025	UNH UnitedHealth Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$418.00 ➝ $310.00
8/5/2025	BMY Bristol Myers Squibb	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/5/2025	BMY Bristol Myers Squibb	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$42.00
8/4/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$40.00 ➝ $31.00
8/4/2025	UNH UnitedHealth Group	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$306.00 ➝ $267.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	6.31	$15.14 per share	13.30	($0.08) per share	-2,517.00
AMGN Amgen	$33.42B	4.66	$30.85 per share	9.38	$13.80 per share	20.97
BMY Bristol Myers Squibb	$48.30B	2.02	$6.05 per share	7.91	$8.59 per share	5.57
JNJ Johnson & Johnson	$88.82B	4.73	$13.23 per share	13.17	$32.58 per share	5.35
MRK Merck & Co., Inc.	$64.17B	3.22	$9.75 per share	8.48	$19.64 per share	4.21
MRNA Moderna	$3.24B	3.23	N/A	N/A	$24.16 per share	1.11
UNH UnitedHealth Group	$400.28B	0.62	$33.65 per share	8.08	$110.93 per share	2.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.10	95.89	14.40	1.28	6.45%	699.66%	13.64%	10/29/2025 (Estimated)
AMGN Amgen	$4.09B	$12.23	23.66	13.53	2.46	18.96%	174.71%	13.12%	10/29/2025 (Estimated)
BMY Bristol Myers Squibb	-$8.95B	$2.48	19.28	7.85	2.38	10.58%	80.04%	14.69%	10/30/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$9.35	18.64	15.74	2.20	25.00%	32.49%	13.00%	10/21/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.49	12.74	8.35	0.85	25.79%	41.05%	16.55%	10/30/2025 (Estimated)
MRNA Moderna	-$3.56B	-$7.53	N/A	N/A	N/A	-94.31%	-25.96%	-20.09%	N/A
UNH UnitedHealth Group	$14.41B	$23.08	11.78	8.19	1.69	5.04%	23.32%	7.66%	10/21/2025 (Estimated)

Latest MRK, JNJ, UNH, AMGN, MRNA, BMY, and ABBV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	AMGN Amgen	$5.28	$6.02	+$0.74	$2.65	$8.86 billion	$9.18 billion
8/1/2025	Q2 2025	MRNA Moderna	-$2.99	-$2.13	+$0.86	-$2.13	$116.26 million	$142.00 million
7/31/2025	Q2 2025	ABBV AbbVie	$3.24	$2.97	-$0.27	$0.52	$14.93 billion	$15.42 billion
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.07	$1.46	+$0.39	$0.64	$11.32 billion	$12.27 billion
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	$2.13	+$0.10	$1.76	$15.92 billion	$15.81 billion
7/29/2025	Q2 2025	UNH UnitedHealth Group	$4.45	$4.08	-$0.37	$3.74	$111.75 billion	$111.62 billion
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.68	$2.77	+$0.09	$2.29	$22.85 billion	$23.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.26%	N/A	312.38%	53 Years
AMGN Amgen	$9.52	3.29%	N/A	77.84%	14 Years
BMY Bristol Myers Squibb	$2.48	5.19%	N/A	100.00%	17 Years
JNJ Johnson & Johnson	$5.20	2.98%	N/A	55.61%	64 Years
MRK Merck & Co., Inc.	$3.24	3.92%	N/A	49.92%	14 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
UNH UnitedHealth Group	$8.84	3.25%	N/A	38.30%	15 Years

Latest MRK, JNJ, UNH, AMGN, MRNA, BMY, and ABBV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/22/2025	MRK Merck & Co., Inc.	quarterly	$0.81	3.97%	9/15/2025	9/15/2025	10/7/2025
8/13/2025	UNH UnitedHealth Group	quarterly	$2.21	3.38%		9/15/2025	9/23/2025
8/1/2025	AMGN Amgen	quarterly	$2.38	3.21%	8/22/2025	8/22/2025	9/12/2025
7/16/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.35%	8/26/2025	8/26/2025	9/9/2025
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025
6/5/2025	UNH UnitedHealth Group	quarterly	$2.21	3%	6/16/2025	6/16/2025	6/24/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.74	0.61
AMGN Amgen	7.24	1.31	0.98
BMY Bristol Myers Squibb	2.54	1.21	1.11
JNJ Johnson & Johnson	0.50	1.01	0.76
MRK Merck & Co., Inc.	0.69	1.42	1.17
MRNA Moderna	N/A	3.93	3.77
UNH UnitedHealth Group	0.73	0.85	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
AMGN Amgen	76.50%
BMY Bristol Myers Squibb	76.41%
JNJ Johnson & Johnson	69.55%
MRK Merck & Co., Inc.	76.07%
MRNA Moderna	75.33%
UNH UnitedHealth Group	87.86%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
AMGN Amgen	0.76%
BMY Bristol Myers Squibb	0.09%
JNJ Johnson & Johnson	0.16%
MRK Merck & Co., Inc.	0.13%
MRNA Moderna	11.00%
UNH UnitedHealth Group	0.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
AMGN Amgen	28,000	538.36 million	534.27 million	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.50 billion	2.49 billion	Optionable
MRNA Moderna	5,800	389.08 million	346.28 million	Optionable
UNH UnitedHealth Group	400,000	905.67 million	904.60 million	Optionable

MRK, JNJ, UNH, AMGN, MRNA, BMY, and ABBV Headlines

Recent News About These Companies

Dividend Stocks To Add to Your Watchlist - August 13th

5 hours ago | marketbeat.com

Why UnitedHealth Stock Was Climbing on Wednesday

August 13 at 5:04 PM | fool.com

New York man charged with cyberstalking widow of slain UnitedHealthcare CEO Brian Thompson

August 13 at 4:38 PM | cnbc.com

Medical Stocks To Follow Today - August 13th

August 13 at 3:01 PM | marketbeat.com

Healthcare Stocks Worth Watching - August 13th

August 13 at 3:01 PM | marketbeat.com

UnitedHealth Group Incorporated (NYSE:UNH) Plans Quarterly Dividend of $2.21

August 13 at 11:59 AM | marketbeat.com

UnitedHealth Group (NYSE:UNH) Shares Up 3.2% After Dividend Announcement

August 13 at 11:17 AM | marketbeat.com

Dow Jones: Sector Rotation Lifts Industrials, UnitedHealth Tops Dow Stock Movers

August 13 at 10:48 AM | fxempire.comF

Should You Invest in UnitedHealth (UNH) Based on Bullish Wall Street Views?

August 13 at 10:31 AM | zacks.com

Boston Partners Has $1.06 Billion Holdings in UnitedHealth Group Incorporated (NYSE:UNH)

August 13 at 7:51 AM | marketbeat.com

Heck Capital Advisors LLC Trims Stake in UnitedHealth Group Incorporated (NYSE:UNH)

August 13 at 7:40 AM | marketbeat.com

E Fund Management Co. Ltd. Acquires 1,844 Shares of UnitedHealth Group Incorporated (NYSE:UNH)

August 13 at 7:30 AM | marketbeat.com

Tokio Marine Asset Management Co. Ltd. Has $56.41 Million Holdings in UnitedHealth Group Incorporated (NYSE:UNH)

August 13 at 7:16 AM | marketbeat.com

UnitedHealth Group announces $2.21 per share dividend

August 13 at 7:13 AM | investing.com

Triglav Skladi D.O.O. Has $20.71 Million Holdings in UnitedHealth Group Incorporated (NYSE:UNH)

August 13 at 7:06 AM | marketbeat.com

7,500 Shares in UnitedHealth Group Incorporated (NYSE:UNH) Bought by S Bank Fund Management Ltd

August 13 at 6:59 AM | marketbeat.com

Gulf International Bank UK Ltd Sells 19,166 Shares of UnitedHealth Group Incorporated (NYSE:UNH)

August 13 at 6:50 AM | marketbeat.com

UnitedHealth Group Board Authorizes Payment of Quarterly Dividend

August 13 at 6:50 AM | businesswire.com

National Pension Service Has $958.55 Million Stock Position in UnitedHealth Group Incorporated (NYSE:UNH)

August 13 at 6:38 AM | marketbeat.com

UnitedHealth Group Incorporated (NYSE:UNH) Shares Sold by GKV Capital Management Co. Inc.

August 13 at 6:28 AM | marketbeat.com

Mondrian Investment Partners LTD Reduces Holdings in UnitedHealth Group Incorporated (NYSE:UNH)

August 13 at 6:15 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MRK, JNJ, UNH, AMGN, MRNA, BMY, and ABBV Company Descriptions

AbbVie NYSE:ABBV

$201.36 +2.72 (+1.37%)

Closing price 03:59 PM Eastern

Extended Trading

$201.40 +0.04 (+0.02%)

As of 08:00 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Amgen NASDAQ:AMGN

$289.33 +4.35 (+1.53%)

Closing price 04:00 PM Eastern

Extended Trading

$288.88 -0.45 (-0.16%)

As of 07:59 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Bristol Myers Squibb NYSE:BMY

$47.82 +1.27 (+2.73%)

Closing price 03:59 PM Eastern

Extended Trading

$47.72 -0.10 (-0.22%)

As of 07:56 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Johnson & Johnson NYSE:JNJ

$174.29 +1.51 (+0.87%)

Closing price 03:59 PM Eastern

Extended Trading

$174.28 0.00 (0.00%)

As of 07:57 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Merck & Co., Inc. NYSE:MRK

$82.67 +2.37 (+2.95%)

Closing price 03:59 PM Eastern

Extended Trading

$82.50 -0.17 (-0.21%)

As of 07:58 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Moderna NASDAQ:MRNA

$26.89 +1.23 (+4.79%)

Closing price 04:00 PM Eastern

Extended Trading

$26.92 +0.03 (+0.11%)

As of 08:00 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

UnitedHealth Group NYSE:UNH

$271.92 +10.35 (+3.96%)

Closing price 03:59 PM Eastern

Extended Trading

$274.95 +3.03 (+1.11%)

As of 08:00 PM Eastern

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MRK, JNJ, UNH, AMGN, MRNA, BMY, and ABBV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MRK, JNJ, UNH, AMGN, MRNA, BMY, and ABBV Earnings

Compare Dividends

Latest MRK, JNJ, UNH, AMGN, MRNA, BMY, and ABBV Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MRK, JNJ, UNH, AMGN, MRNA, BMY, and ABBV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MRK, JNJ, UNH, AMGN, MRNA, BMY, and ABBV Company Descriptions

AbbVie NYSE:ABBV

Amgen NASDAQ:AMGN

Bristol Myers Squibb NYSE:BMY

Johnson & Johnson NYSE:JNJ

Merck & Co., Inc. NYSE:MRK

Moderna NASDAQ:MRNA

UnitedHealth Group NYSE:UNH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools